RAM
CRSP icon

Riggs Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Riggs Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-200
Closed -$9.73K – 297
2025
Q2 		$9.73K Sell
200
-8
-4% -$310 ﹤0.01% 333
2025
Q1 		$7.08K Sell
208
-192
-48% -$8.14K ﹤0.01% 294
2024
Q4 		$15.5K Hold
400
– – ﹤0.01% 228
2024
Q3 		$18.8K Sell
400
-100
-20% -$5.07K 0.01% 211
2024
Q2 		$27K Hold
500
– – 0.01% 174
2024
Q1 		$34.1K Buy
500
+200
+67% +$14.3K 0.01% 158
2023
Q4 		$18.8K Buy
300
+200
+200% +$11.1K 0.01% 188
2023
Q3 		$4.54K Hold
100
– – ﹤0.01% 299
2023
Q2 		$5.61K Buy
+100
New +$5.67K ﹤0.01% 275

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Riggs Asset Management's CRSP Position: Q3 2025 in Review

Riggs Asset Management sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 200 shares — an estimated $9.73K sold.

Riggs Asset Management first reported a position in CRSP in Q2 2023 and held it in 9 quarters. The position peaked at $34.1K in Q1 2024. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Riggs Asset Management reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Riggs Asset Management sold 200 CRISPR Therapeutics shares in Q3 2025, an estimated $9.73K.
  • Riggs Asset Management first reported a position in CRISPR Therapeutics in Q2 2023 and held it in 9 quarters.
  • Riggs Asset Management's CRISPR Therapeutics position peaked at $34.1K in Q1 2024.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Riggs Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.